Ed Ross – North America

Ed Ross – North America

Ed Ross is a proven startup and major medtech company executive with over 30 years’ experience spanning devices, biotech and pharmaceutical products. Specializing in the premarket, launch and early stage growth of major medical innovations, Ed has developed a strong operational track record across sales and marketing, operations, business and product development, reimbursement and partnerships in a wide variety of therapeutic areas. Beginning in medical supply distribution and progressing in management responsibilities through major medical leaders such as American Hospital Supply and Zimmer, Ed led the development and commercialization of major innovative combination devices and therapeutics business units at Genetics Institute and Anika Therapeutics moving onto building and taking startups such as Gliatech and Clozex Medical/ 3M through public offerings and acquisition. Ed has led startups as CEO to successful exit, raised over $50 million from angel and venture sources and created and led dozens of partnerships.

Ed has developed innovative strategies leading to successful introductions as well as strong, responsive operations built on strong teams and processes. He has built both direct and indirect sales and clinical representation teams on a global basis as well as development and commercialization partnerships in the US, Canada, Europe, Japan and Asia. In addition, Ed’s work has led to several national awards for innovative technology and education.

Most recently, Ed leads a operational consulting and investment firm, focusing on strategic and operational leadership for startups in medtech/ biotech, entertainment and software products and services. An experienced and active angel investor as member with some leading angel groups, Ed has served on several startup boards and as well as in non-profit organizations. Ed is based in the Boston, Massachusetts area with experience and operating focus throughout North America.
Ed joined VISION in 2019 and brings a wealth of commercialization experience and
advisory to our Medical Technology and Life Sciences Division.